Financial Information

Trinity Delta – Hikma licence milestone achieved

13 January 2023

Trinity Delta – Getting the chemistry right

20 December 2022

TRINITY DELTA – SPECIALTY HOSPITAL PRODUCTS FORMULATION COLLABORATION

10 November 2022

Trinity Delta – AT247 Phase I pump data confirms promising profile

11 October 2022

Trinity Delta – Broadening opportunities and preparing for the future

21 September 2022

Trinity Delta – Key clinical diabetes events on track for H2 2022

8 September 2022

Trinity Delta – Arecor Therapeutics acquisition of Tetris Pharma and £6m equity raise

9 August 2022

Trinity Delta – AT278 hits the sweet spot

31 May 2022

Arecor Therapeutics Annual Report and Accounts 2021

27 April 2022

Trinity Delta – Arecor Therapeutics: Ambitious, focussed, and delivering on its promise

25 April 2022

Arecor Trinity Delta Formulation Expertise Exemplified in Diabetes

25 January 2022

Proactive Investors interview – Arecor Therapeutics “looking forward to another successful year”

19 January 2023

Proactive Investors interview – Arecor Therapeutics’ scientist hopeful that artificial pancreas “edging closer”

15 November 2022

Proactive Investors interview – Arecor’s study shows rapid-acting insulin could enable artificial pancreas system

12 October 2022

Proactive Investors interview – CEO talks through interims, clinical trials and growing momentum

9 September 2022

Interim Results for six months ended 30 June 2022

8 September 2022

Proactive Investors interview – Tetris Pharma acquisition plans and focus on key product Ogluo

5 August 2022

Tetris Pharma Acquisition Investor Meet Company Presentation

4 August 2022

Arecor Proactive Investors Interview – Collaboration with global pharmaceutical company

20 June 2022

KOL Webinar on the Need for Concentrated and Rapid Acting Insulin

31 May 2022

Arecor Preliminary Results Presentation

25 April 2022

Arecor Proactive Presentation

22 October 2021

Interim results for the six months ended 30 June 2021

23 September 2021